Published in final edited form as:

Mol Pharm. 2010 June 7; 7(3): 844–853. doi:10.1021/mp100003r.

Development of a novel self micro-emulsifying drug delivery system (SMEDDS) for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction

Bokai Lei^{1,2}, Weibin Zha^{1,3}, Yun Wang^{1,3}, Cong Wen², Elaine J Stude¹, Xuan Wang¹, Fang Jin^{2,*}, Guangji Wang³, Luyong Zhang³, and Huiping Zhou^{1,*}

¹Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, 23298, USA

²Shanghai Institute of Pharmaceutical Industry, Shanghai, 200040, China

³China Pharmaceutical University, Nanjing, 210009, China

Abstract

The development of HIV protease inhibitors (PIs) has been one of the most significant advances of the past decade in controlling HIV infection. Unfortunately, the benefits of HIV PIs are compromised by serious side effects. One of the most frequent and deleterious side effects of HIV PIs is severe gastrointestinal (GI) disorders including mucosal erosions, epithelial barrier dysfunction, and leak-flux diarrhea, which occurs in 16–62% of patients on HIV PIs. Although the underlying mechanisms behind HIV PI-associated serious adverse side effects remain to be identified, our recent studies have shown that activation of endoplasmic reticulum (ER) stress response plays a critical role in HIV PI-induced GI complications. The objective of this study was to develop a novel self micro-emulsifying drug delivery system (SMEDDS) using various antioxidants as surfactants and co-surfactants to reduce the GI side effects of the most commonly used HIV PI, ritonavir. The biological activities of this SMEDDS of ritonavir were compared with that of Norvir[®], which is currently used in the clinic. Rat normal intestinal epithelial cells (IEC-6) and mouse Raw 264.7 macrophages were used to examine the effect of new SMEDDS of ritonavir on activation of ER stress and oxidative stress. The Sprague-Dawley rats and C57/BL6 mice were used for pharmacokinetic studies and *in vivo* studies. The intracellular and plasma drug concentrations were determined by HPLC analysis. Activation of ER stress was detected by western blot analysis and secreted alkaline phosphatase (SEAP) reporter assay. Reactive oxygen species (ROS) was measured using dichlorodihydrofluorescein diacetate as a probe. Cell viability was determined by Roche's cell proliferation reagent WST-1. Protein levels of inflammatory cytokines (TNF- α and IL-6) were determined by Enzyme-linked immunosorbent assays (ELISA). The intestinal permeability was assessed by luminal enteral administration of fluorescein isothiocyanate conjugated dextran (FITC-dextran, 4 kDa). The pathologic changes in intestine were determined by histological examination. The results indicated that incorporation of antioxidants in this new SMEDDS not only significantly reduced ritonavir-induced ER stress activation, ROS production and apoptosis in intestinal epithelial cells and macrophages, but also improved the solubility, stability and bioavailability of ritonavir, and significantly reduced ritonavir-induced disruption of intestinal barrier function *in vivo*. In conclusion, this new SMEDDS of ritonavir has better bioavailability and less GI side effects as compared to Norvir[®]. This new SMEDDS can be used for other HIV PIs and any insoluble anti-viral drug with serious GI side effects.

Correspondence to: Huiping Zhou, Ph.D., Department of Microbiology & Immunology, Virginia Commonwealth University, P.O. Box 980678, Richmond, VA 23298-0678, Tel: 804-828-6817, Fax: 804-828-0676, hzhou@vcu.edu. Fang Jin, Ph.D, National key laboratory, Shanghai Institute of Pharmaceutical Industry, Shanghai, China, 200040, Tel: (86) 21-6247-9808, Fax: (86) 21- 6279-1715, jfsipi@163.com.

Keywords

Ritonavir; antioxidants; SMEDDS; ER stress; inflammation

Introduction

The development of HIV PIs has been one of the most significant advances of the past decade in controlling HIV infection. Incorporation of HIV PIs in highly active antiretroviral therapy (HAART) has markedly decreased mortality and morbidity of patients with HIV infection. Despite the clinical successes of HIV PIs, accumulating clinical evidence suggests that the benefits of HIV PIs are compromised by various undesirable side effects^{1–7}. One of the most frequent and deleterious side effects of HIV PIs is their necrotizing effects on gut mucosa including the impairment of epithelial barrier function, which occurs in 16–62% of patients on HAART^{8, 9}. At present, the relationship between HAART and GI complications, and the underlying mechanisms behind HIV PI-associated intestinal barrier dysfunction are unknown. Therapeutic and preventive strategies are currently unavailable.

The endoplasmic reticulum (ER) plays a major role in regulating the synthesis, folding, and orderly transport of proteins¹⁰. The ER has evolved highly specific signaling pathways, collectively termed the unfolded protein response (UPR), to ensure that its protein-folding capacity is not overwhelmed under various stresses. It has been reported that the UPR can be activated by disruption of intraluminal calcium homeostasis, alteration of protein glycosylation, glucose deprivation, virus infection, and changes in redox status¹¹. The protein folding capacity of ER is significantly impacted by the reactive oxygen species (ROS) levels. Persistent generation of ROS in the ER results in the activation of the UPR and plays fundamental roles in the pathogenesis of multiple human diseases including various liver diseases, inflammatory bowel disease (IBD), and drug-induced tissue injury¹². We have previously reported that HIV PIs activated the UPR and disrupted lipid metabolism in macrophages and hepatocytes^{13, 14}. Our most recent studies have shown that ER stress activation plays a critical role in HIV PI-induced disruption of intestinal barrier integrity¹⁵, suggesting that inhibition of the ER stress response represents a potential therapeutic target for HIV PI-induced GI side effects.

Self emulsifying drug delivery systems (SEDDS) are isotropic mixtures of oils, surfactants, solvents and co-solvents/surfactants and have been used for oral delivery of various hydrophobic drugs including HIV PIs, Norvir® (ritonavir) and Fortovase (saquinavir)¹⁶. A self microemulsifying drug delivery system (SMEDDS) is a novel drug delivery system based on the intrinsic chemical property of the drug formulation. SMEDDS offers numerous advantages such as spontaneous formation, thermodynamic stability, improved bioavailability, and ease of manufacture. The main objective of this study was to develop a novel SMEDDS for ritonavir using antioxidants as surfactants and co-surfactants to inhibit ritonavir-induced oxidative stress and the UPR activation and reduce the GI side effects associated with currently used SEDDS for ritonavir, Norvir®.

Materials and Methods

Materials

Antibodies against C/EBP homologous protein (CHOP), lamin B, and horseradish peroxidase (HRP)-conjugated donkey anti-goat IgG were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody against β -actin was from Calbiochem (San Diego, CA). Bio-Rad protein assay reagent, Criterion XT Precast Gel, HRP-conjugated goat anti-rabbit IgG and Precision Plus Protein Kaleidoscope Standards were obtained from Bio-Rad (Hercules, CA).

Ritonavir was purchased from XIAMEN MCHEM laboratories LTD (Xiamen, China). Norvir® was Abbott Laboratories (Abbott Park, IL). Biomax MS films were obtained from Eastman Kodak (Rochester, NY). Great EscAPE™ SEAP Reporter Assay Kit was obtained from Clontech Laboratories (Mountain View, CA.). Mouse TNF- α and IL-6 ELISA Max™ Set Deluxe Kits were from BioLegend (San Diego, CA). Dichlorodihydrofluorescein diacetate (DCFDA) and cell culture media were from Invitrogen, Ltd (Paisley, UK). All other chemical reagents were from Sigma (St. Louis, MO).

Solubility studies

The solubility of ritonavir in various oils and surfactants was determined. A total 1 ml of each selected vehicle was added into a screw capped test tube containing 25 mg of ritonavir and mixed by vortexing. After visual assessment of solubility, additional ritonavir was added. The mixtures were shaken with a shaker at 37°C for 24 h. After reaching equilibrium, the mixtures were centrifuged at 3,000 rpm for 5 min, and excess insoluble ritonavir was discarded by filtration using a Whatman filter. The free drug concentration of ritonavir was determined by HPLC. In order to save ritonavir, we stopped the solubility test in ethanol and oleic acid after the amount of ritonavir added was up to 150 mg. Table 1 shows the results of the solubility studies.

Preparation of ritonavir SMEDDS

A series of SMEDDS were prepared in each formulation by varying the ratio of oil, surfactant, co-surfactant based on results of *in vitro* antioxidant effects and inhibition of the ER stress response. A SMEDDS was prepared with oil (ethyl linoleate, vitamin E, oleic acid), surfactant (cremophor EL), cosurfactant (1% vitamin C in ethanol), and ritonavir. The level of ritonavir was kept constant (10% w/v) in the total volume. Briefly, ritonavir was dissolved in co-surfactant in a glass vial. Oil and surfactant were accurately weighed and added into the glass vial containing ritonavir. Then, the components were mixed by gentle stirring and vortexing until ritonavir was completely dissolved. The blank SMEDDS was prepared by the same method as described above without ritonavir. The mixtures of ritonavir SMEDDS and blank SMEDDS were stored at 4°C until further use.

Characterization of SMEDDS: particle size analysis and zeta potential

Twenty-five microliters of SMEDDS formulation was diluted to 2.5mL of deionized water in a beaker and gently mixed using a glass rod. The particle size and zeta potential of the resulting microemulsion was determined by the dynamic light scattering technique with a NICOMP particle sizing system (ZPW388 version 1.75). The Intensity –WT Gaussian distribution mean diameters and polydispersity index were determined. For the zeta potential, the microemulsion was placed in the electrophoretic cell and the average surface charge was recorded.

Stability of ritonavir SMEDDS—The ritonavir SMEDDS was stored at 4°C for three months. The ritonavir content of the samples was analyzed by HPLC and the particle size was determined as described in the previous section.

Cell culture and treatment—The IEC-6 cell line was purchased from the American Type Culture Collection (ATCC) at passage 13 and used at passages 15–20 for the current experiments. The cell line was derived from normal rat intestine and was developed and characterized by Quaroni *et al*¹². They are nontumorigenic and retain the undifferentiated character of epithelial stem cells. IEC-6 cells were cultured in DMEM supplemented with 10% FBS, 0.1U/ml insulin, 100 U/ml penicillin, and 100 μ g/ml streptomycin at 37°C with 5% CO₂. Mouse RAW264.7 macrophages from ATCC were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 μ g/ml streptomycin at 37°C with 5% CO₂. Cells

from passages six to nine were used in these studies. The ritonavir SMEDDS, blank SMEDDS and Norvir were diluted in DMEM and ritonavir was dissolved in DMSO. The diluted ritonavir SMEDDS, Norvir® or ritonavir were added directly into cell culture medium to a final concentration of 15 or 25 μM and incubated for 4–24 h.

Quantification of ritonavir using High Performance Liquid Chromatography (HPLC) Assay—A HPLC was used to quantify ritonavir concentrations in IECs and mouse serum according to the method developed by Granda, et al. with some modifications¹⁷. An Agilent 1200 Series HPLC system and a Beckman C18 reverse phase column (5 μm , 4.6mm $\times$ 25 cm) were used to quantify the ritonavir in cells and medium. The mobile phase was acetonitrile: 1% acetic acid (50:50 to 60:40 v/v in 15 min). The samples were extracted with acetonitrile with a ratio of 40:60 (v/v) followed by centrifugation. The ritonavir was detected at a wavelength of 205 nm. A standard curve of ritonavir was constructed using weighted linear regression of peak area ratio values of the calibration standards.

IEC-6 cells were seeded on 6-well plates at a density of 6×10^5 for 24 h, and then treated with 15 μM of ritonavir in SMEDDS, Norvir® or DMSO for various time periods 0.25, 0.5, 1, 2, 4, 8, and 24 h. Ritonavir in the cells was extracted using methanol and subjected to HPLC analysis. The intracellular ritonavir was normalized with the total protein amount.

Cell viability assay

The cytotoxicities of ritonavir in DMSO, ritonavir SMEDDS and Norvir® in IEC-6 cells were assessed using Cell Proliferation Reagent WST-1 from Roche Molecular Biochemicals. IEC 6 cells were seeded onto 96-well plates for overnight, then treated with ritonavir (0–50 μM) in different formulations for 24 h. At the end of treatment, 10 μl of cell proliferation reagent WST-1 was added into each well. Cells were incubated at 37°C for 1 h. The absorbance of the samples at 450 nm was measured against a background control using a 96-well plate reader. The percentage of viable cells under each treatment condition was determined relative to the negative control.

Western blot analysis

Total nuclear proteins were prepared and the protein levels of CHOP and lamin B or β -actin were detected and analyzed as previously described¹⁴.

Construction of IEC-6 stable cell line expressing secreted alkaline phosphatase (SEAP) and SEAP enzyme activity assay

SEAP is secreted from the ER and its activity is rapidly down-regulated by ER stress independent of transcriptional regulation¹⁴. IEC-6 stable cell line expressing SEAP was established as described previously¹⁵. The SEAP enzyme activity was measured by chemiluminescent assays using Great EscAPe SEAP Detection Kit according to the manufacturer's instructions (Promega).

Enzyme-linked immunosorbent assays (ELISA) of cytokines

Mouse macrophages were treated with 15 μM of ritonavir in different formulations or vehicle control for 24 h. At the end of the treatment, the culture media were collected and centrifuged at $13,000 \times \text{rpm}$ for 5 min. The supernatants were collected and stored in aliquots at -70°C until use. The protein levels of TNF- α and IL-6 in the media were determined by ELISA as described previously⁶. The total protein concentrations of the viable cell pellets were determined using Bio-Rad Protein Assay reagent. Total amounts of the TNF- α and IL-6 in media were normalized to the total protein amounts of the viable cell pellets.

Measurement of intracellular ROS

Dichlorodihydrofluorescein diacetate (H₂DCFDA) is a cell-permanent nonfluorescent dye until the acetate groups are removed by intracellular esterases and oxidation occurs within the cells. Cells were cultured in 12-well plates and treated with 15 μ M of ritonavir with or without various antioxidants (all dissolved in DMSO), ritonavir SMEDDS, Norvir® or blank SMEDDS (diluted in medium) for 4h. Hydrogen peroxide (H₂O₂, final Concentration, 300 μ M) was used as positive control. Following the treatment, cells were washed once with PBS, loaded with 10 μ M H₂DCFDA in serum free DMEM for 30 min at 37°C. After washing with PBS for three times, cells were collected and divided into two fractions. One was resuspended in PBS for measuring protein concentration; the other was resuspended in 0.5 ml of lysis buffer (0.1N NaOH in 50% methanol). The total cell lysate was centrifuged at 5,000 $\times$ rpm for 5min. The supernatant was used to determine the fluorescence intensity using a 96-well plate reader with excitation and emission wavelengths of 485 and 520 nm. The fluorescence values were normalized to protein levels in each sample.

Animal studies

Sprague-Dawley rats (male, 220 to 260 g) were used for *in vivo* pharmacokinetic studies. C57BL/6 wild type (male, 6–8 weeks old, Jackson Laboratories, Bar Harbor, ME) were used to assess the *in vivo* intestinal epithelia function and tissue distribution of ritonavir. Rats and mice were housed and fed standard mouse chow and tap water *ad libitum* throughout the study following protocols approved by the IACUC at Virginia Commonwealth University.

Pharmacokinetic studies of ritonavir SMEDDS

Sprague-Dawley rats (220 to 260 g) were used to compare the pharmacokinetics of ritonavir SMEDDS and Norvir®. Rats were randomly divided into the following ritonavir SMEDDS and Norvir groups (n=3). Drugs were orally administrated at a dose of 50 mg/kg. The blood samples (0.2 mL) were collected from the tail vein at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h. The ritonavir concentrations in plasma were determined by HPLC. Drug and Statistics for Windows (DAS ver1.0) was utilized to analyze the pharmacokinetic parameters of the area under the plasma concentration–time curve (AUC_{0–∞}), the apparent volume of distribution (V_d), total body clearance (CL), elimination half life (t_{1/2β}) and mean residence time (MRT) of ritonavir for each formulation.

The effect of ritonavir SMEDDS on intestinal barrier function

Mice were randomly assigned to the following four groups: Control, blank SMEDDS, ritonavir SMEDDS, and Norvir®. Mice were gavaged daily with ritonavir SMEDDS or Norvir® (50 mg/kg) or control solution for 4 weeks. Animals were monitored daily for appearance of diarrhea, body weight loss and other distress. At the end of treatment, mice were gavaged with FITC-dextran (4 kD) at a dose of 600 mg/kg body weight 4 h before harvest. Blood was collected from the hepatic portal vein. The serum concentration of the FITC-dextran was determined using a fluorescence plate reader with an excitation wavelength at 490 nm and an emission wavelength of 530 nm¹⁵. The plasma concentration of ritonavir was determined by HPLC analysis. The intestines were removed and sections were taken for formalin fixation and histological examination as described previously 15.

Statistical methods

Values are means $\pm$ SD from three to six samples. Western blot results were repeated at least three times. One-way ANOVA was employed to analyze the data. Statistics were performed using Prism 5 (GraphPad, San Diego, CA). The $p < 0.05$ values were considered statistically significant.

Results

Effect of individual antioxidant on ritonavir-induced ROS production in IEC-6 cells

It has been reported that HIV PIs augment production of ROS in various types of cells including macrophages, vascular smooth muscle cells, umbilical vein endothelial cells, adipocytes, and pancreatic β -cells, suggesting that oxidative stress play a role in HIV PI-induced adverse side effect^{18–22}. Our most recent studies found that HIV PI-induced ER stress contributed to disruption of intestinal barrier integrity¹⁵. First, we tested whether the commonly used antioxidants in drug formulations were able to prevent ritonavir-induced ROS production in IEC-6 cells. As shown in Fig. 1, the vitamin C, ethyl linoleate and oleic acid were able to reduce ritonavir-induced ROS production in IEC-6 cells. Similar results were obtained in mouse macrophages (online supplement Fig.1).

Effect of individual antioxidant on ritonavir-induced ER stress in IEC-6 cells

Oxidative stress and ER stress are closely related events. It has been shown that oxidative stress induces UPR activation²³ and antioxidants reduce ER stress and improve the protein folding capacity of ER²⁴. In order to assess the effect of individual antioxidant on ritonavir-induced ER stress activation, we constructed stable IEC-6 cells overexpressing SEAP as described previously. The SEAP is secreted from the ER and its activity is rapidly down-regulated by ER stress independent of transcriptional regulation. As shown in Fig. 2A, ritonavir markedly inhibited SEAP activity (>80%), which was significantly inhibited by vitamin C, vitamin E, ethyl linoleate and oleic acid. We further examined whether these antioxidants were also able to reduce ritonavir-induced UPR activation in IEC-6 cells by detecting the expression of CHOP, the downstream transcriptional factor of the UPR, using Western blot analysis. As shown in Fig. 2B, ritonavir-induced CHOP expression was significantly reduced by vitamin C, ethyl linoleate and oleic acid, while vitamin E had less effect. Similarly, vitamin C, ethyl linoleate and oleic acid also inhibited ritonavir-induced CHOP expression in macrophages (online supplemental Fig.2). These results suggested that these antioxidants were of great potential in the development of a novel ritonavir formulation.

Preparation and characterization of ritonavir SMEDDS

Our previous studies have shown that ritonavir-induced dyslipidemia, inflammation and gastrointestinal barrier dysfunction are linked to ER stress and the UPR activation^{6, 13–15}. It also has been shown that persistent oxidative stress can initiate ER stress response and polyunsaturated fatty acids have beneficial effects on lipid metabolism^{11, 25}. Based on the results of *in vitro* studies, we selected vitamin C, vitamin E, ethyl linoleate, and oleic acid, together with cremophor EL to prepare the ritonavir SMEDDS. A series of ritonavir SMEDDS formulations were prepared. The composition of ritonavir SMEDDS was optimized based on the concentration of oil and emulsifier and particle size. The final formulation of ritonavir SMEDDS consisted of ritonavir (10% w/v), ethyl linoleate (30% v/v), vitamin E (5% v/v), 1% vitamin C in ethanol (20% v/v), cremophor EL (25% v/v) and oleic acid (10% v/v). The blank SMEDDS was prepared with the same amount of each component except ritonavir. Both ritonavir SMEDDS and blank SMEDDS were easily self-emulsified in water.

We further determined the particle size and zeta potential to characterize the particles of ritonavir SMEDDS. The zeta potential is a good estimate of the surface charge of the particles, which is determined from the particle electrophoretic mobility in an electrophoretic cell²⁶. As shown in Fig. 3A, the Intensity-WT Gaussian distribution means of the diameters for blank SMEDDS and ritonavir SMEDDS were 46.1 nm and 81.6 nm, respectively. The incorporation of ritonavir in the SMEDDS increased particle size, but it was less than 100 nm. As shown in Fig. 3B and 3C, the surface charges of blank SMEDDS and ritonavir SMEDDS were similar

(1.70 mv and 1.94 mv). In addition, both blank SMEDDS and ritonavir SMEDDS were narrowly distributed and their polydispersity indexes were under 0.3.

Stability and pharmacokinetic studies of ritonavir SMEDDS

To determine whether this new formulation affected the stability of ritonavir, we compared the stability of ritonavir SMEDDS and Norvir® in culture medium at 37°C. As shown in Fig. 4A, ritonavir SMEDDS was more stable than Norvir®. We further examined the uptake of ritonavir in IEC-6 cells, as shown in Fig. 4B, this SMEDDS more efficiently delivered the encapsulated ritonavir into IEC-6 cells. The *in vivo* pharmacokinetic studies indicated that the bioavailability of ritonavir SMEDDS was better than that of Norvir® as indicated by higher C_{max} and shorter T_{max} (Fig. 4C).

Effect of ritonavir SMEDDS on cell viability in IEC-6 cells

Our previous studies have shown that ritonavir induces cell apoptosis in macrophages, primary hepatocytes and IEC-6 cells^{13–15}. In order to determine whether incorporation of antioxidants in ritonavir SMEDDS is able to prevent ritonavir-induced cell death, we assessed the viability of IEC-6 cells after treatment with ritonavir SMEDDS and Norvir® for 24 h. As shown in Fig. 5, ritonavir SMEDDS had less effect on cell viability compared to Norvir® in IEC-6 cells.

Effect of ritonavir SMEDDS on ROS production in IEC-6 cells

To determine whether incorporation of antioxidants in ritonavir SMEDDS was able to quench ritonavir-induced ROS production, IEC-6 cells were treated with 15 µM ritonavir in DMSO, ritonavir SMEDDS or Norvir® for 4 h; the intracellular levels of ROS were measured as described in “Methods”. As shown in Fig. 6, ritonavir-induced ROS production was inhibited by ritonavir SMEDDS, suggesting that incorporation of antioxidants in ritonavir SMEDDS helped reduce ritonavir-induced oxidative stress. Similar results were obtained in macrophages (data not shown).

Effect of ritonavir SMEDDS on ER stress and UPR activation in IEC-6 cells

In order to assess the effect of ritonavir SMEDDS on ER stress and UPR activation, we compared the effects of ritonavir SMEDDS and Norvir® on SEAP secretion and CHOP expression in IEC-6 cells as described in previous sections. As shown in Fig. 7A, Norvir® inhibited SEAP activity by 35%, but ritonavir SEMDDS had little effect. Similarly, ritonavir SMEDDS had less effect on CHOP expression. Both ritonavir in DMSO and Norvir® significantly induced CHOP expression in IEC-6 cells (Fig. 7B). Similarly, ritonavir SMEDDS had no significant effect on UPR activation in macrophages (online supplement Fig. 3)

Effect of ritonavir SMEDDS on intestinal epithelial integrity *in vivo*

We have recently shown that UPR activation greatly contributes to ritonavir-induced disruption of intestinal barrier function¹⁵. Ritonavir-induced intestinal epithelial damage was significantly reduced in CHOP knockout mice. To further evaluate the effect of ritonavir SMEDDS on intestinal epithelial integrity, we examined the effects of ritonavir SMEDDS and Norvir® on intestinal permeability and intestinal tissue damage in wild type C57/BL6 mice. As shown in Fig. 8A, after 4-week treatment, Norvir® and ritonavir SMEDDS increased intestinal permeability by 260% and 140%, respectively. Incorporation of antioxidants significantly prevented ritonavir-induced increase of intestinal permeability. Histological examination further confirmed that ritonavir-induced intestinal tissue damage was also significantly reduced in ritonavir SMEDDS-treated mice (Fig. 8B).

Discussion

HIV PIs are currently among the preferred components used in combination with other drug as part of HAART, which has changed HIV infection from invariably lethal to a manageable chronic condition. However, the benefits of HIV PIs are compromised by a number of clinically significant adverse side effects²⁷. HIV PI-induced dysfunction of gastrointestinal barrier has recently been recognized as a paramount factor in the pathogenesis of HIV progression and HIV PI-associated cardiovascular complication^{9, 28}. The elevated plasma endotoxin, a consequence of microbial translocation due to leaky gut, and subsequent activation of systemic inflammatory response are the hallmarks of progressive HIV infection and better predict disease outcome than plasma viral load^{29–31}. A number of studies have shown that induction of oxidative stress and ER stress contributes to the HIV PI-induced various side effects such as dysregulation of lipid metabolism, insulin resistance, inflammation and disruption of intestinal barrier function². Development of novel strategies to prevent HIV PI-induced clinical complications is of great importance.

Ritonavir is the most commonly used HIV PI and is presently sold in a soft gelatin capsule dosage form for oral administration under the trade name Norvir®. Norvir® uses a self emulsifying drug delivery system (SEDDS) and it forms a milk-like emulsion in water. The current study developed a novel SMEDDS for ritonavir using various antioxidants and evaluated its potential effects on reducing ritonavir-induced oxidative stress and UPR activation in intestinal epithelial cells and further studied its pharmacokinetics and effect on intestinal barrier function *in vivo*.

Of many drug delivery systems, SMEDDS have attracted growing interest due to their excellent efficiency in improving the drug solubility and have been successfully used for oral delivery of hydrophobic drugs^{16, 32–34}. SMEDDS forms fine and stable oil-in-water micro-emulsions upon aqueous dilution owing to the gentle agitation of the gastrointestinal fluids¹⁶. In this study, we used an oily antioxidants mixture (ethyl linoleate, oleic acid and vitamin E) as the oil phase and successfully developed a novel SEMDDS for ritonavir. The results indicate that incorporation of ritonavir in SMEDDS significantly improved its solubility in the aqueous phase. After dilution in an aqueous solution, nanoscale droplets (<100 nm) were formed (Fig. 3). Also, there was no precipitation of ritonavir observed when the SMEDDS were diluted in the cell culture media or deionized water for over 24 h. It is important to note that the formation of micro-emulsions depends on multiple factors including physicochemical characteristics of the drug, surfactants selection, usage of co-solvent and proportion of oil and surfactant. The inclusion of drugs within SEMDDS will affect their performance if the drug is able to compete with water for hydrogen bonding interactions³⁵. We found that the inclusion of ritonavir enlarged the mean particles size up to 35 nm (Fig.3) compared to the blank micro-emulsion, but it was still within the 100 nm scale. We further examined the zeta potential of ritonavir SMEDDS. The zeta potential is often used to estimate the surface charge of the particles, which is determined from the particle electrophoretic mobility in an electrophoretic cell. The microemulsions of ritonavir show low but positive surface charge by absorption of ions from medium. The positive surface charge benefits the small droplets of microemulsion penetrating into the intestinal mucus layers, which show negative charge and enhances oral absorption³⁶. Both *in vitro* and *in vivo* pharmacokinetic studies have shown that this SMEDDS significantly improved the bioavailability of ritonavir indicated by higher C_{max} and faster T_{max}. The higher plasma concentration tends to more efficiently distribute the drug into target tissues. In addition, the shorter T_{max} indicates the faster onset of action.

Oxidative stress and ER stress greatly contribute to HIV PI-induced side effects. Overproduction of ROS is closely related to the UPR activation in ER. Numerous studies have shown that antioxidants can reduce ER stress and improve ER function²⁴. Our studies

demonstrated that incorporation of antioxidants in this SMEDDS not only significantly reduced ritonavir-induced ROS formation but also inhibited the UPR activation both in IEC-6 cells (Fig. 6 and 7) and macrophages (online supplemental Fig. 1–3). Our recent studies have shown that upregulation of CHOP expression plays a critical role in HIV PI-induced intestinal tissue damage¹⁵. The *in vivo* studies further demonstrated that this new ritonavir SMEDDS causes less damage to intestinal epithelia compared to Norvir® (Fig. 8).

Inflammation plays a very important role in various diseases including cardiovascular diseases and drug-induced tissue damage^{37–40}. We have previously shown that HIV PI-induced ER stress is associated with the increase of TNF- α and IL-6 expression in macrophages⁶. The inflammatory cytokines expression was associated with the ROS production in macrophages⁴¹. We also found that antioxidants used in ritonavir SMEDDS was able to inhibit ritonavir-induced TNF- α and IL-6 expression in macrophages (data not shown). The ritonavir SMEDDS had less effect on TNF- α and IL-6 expression compared to Norvir® (online supplemental Fig. 4). In addition to the direct effect of HIV PI on macrophages, gut microbial translocation due to the intestinal barrier dysfunction plays a critical role in activating systemic inflammatory response. Our preliminary studies indicate that Norvir® significantly increased plasma endotoxin levels, but ritonavir SMEDDS has less effect (online supplemental Fig. 5).

In summary, the intestinal epithelium constitutes the largest and most important barrier against the external environment. Drug-induced disruption of the intestinal barrier function occurs commonly in the clinic, especially in HIV-infected patients. The current study provided important evidence for the potential application of pharmaceutical formulations in reducing HIV PI-induced intestinal barrier dysfunction. This novel SMEDDS using antioxidants as surfactants and co-surfactants represents a new strategy to improve the drug bioavailability and reduce drug-induced tissue damage. The application of this new SMEDDS is not limited to HIV PIs. It also can be used for any other lipophilic drug with serious GI side effects.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work is supported by grants from the National Institutes of Health (R21AI068432, R01AT004148, and R01AI057189) and China Scholarship Council.

List of abbreviations at the end of the manuscript

CHOP	C/EBP homologous protein
DCFDA	Dichlorodihydrofluorescein diacetate
ELISA	Enzyme-linked immunosorbent assays
ER stress	endoplasmic reticulum stress
FITC-dextran	fluorescein isothiocyanate conjugated dextran
GI	gastrointestinal
HAART	highly active antiretroviral therapy
IBD	inflammatory bowel disease
IEC-6	intestinal epithelial cells
IL-6	interleukin-6

ROS	Reactive oxygen species
SEAP	secreted alkaline phosphatase
SMEDDS	self micro-emulsifying drug delivery system
TNF- α	Tumor necrosis factor- α
UPR	unfolded protein response

References

- Hui DY. HIV protease inhibitors and atherosclerosis. *J Clin. Invest* 2003;111:317–318. [PubMed: 12569155]
- Clotet B, Negro E. HIV protease inhibitors and dyslipidemia. *AIDS Rev* 2003;5:19–24. [PubMed: 12875104]
- Spector AA. HIV protease inhibitors and hyperlipidemia: a fatty acid connection. *Arterioscler. Thromb. Vasc. Biol* 2006;26:7–9. [PubMed: 16373621]
- Kudlow BA, Jameson SA, Kennedy BK. HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. *AIDS* 2005;19:1565–1573. [PubMed: 16184025]
- Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. *Antiviral Res* 2000;47:121–129. [PubMed: 10996400]
- Zhou H, Jarujaron S, Gurley EC, Chen L, Ding H, Studer E, Pandak WM Jr, Hu W, Zou T, Wang JY, Hylemon PB. HIV protease inhibitors increase TNF- α and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. *Atherosclerosis* 2007;195:e134–e143. [PubMed: 17531241]
- Flexner C. HIV-protease inhibitors. *N. Engl. J. Med* 1998;338:1281–1292. [PubMed: 9562584]
- Bode H, Schmidt W, Schulzke JD, Fromm M, Zippel T, Wahnschaffe U, Bendfeldt K, Riecken EO, Ullrich R. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6. *AIDS* 1999;13:2595–2597. [PubMed: 10630532]
- Bode H, Lenzner L, Kraemer OH, Kroesen AJ, Bendfeldt K, Schulzke JD, Fromm M, Stoltenburg-Didinger G, Zeitz M, Ullrich R. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. *Antivir. Ther* 2005;10:645–655. [PubMed: 16152758]
- Schroder M, Kaufman RJ. ER stress and the unfolded protein response. *Mutat. Res* 2005;569:29–63. [PubMed: 15603751]
- Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? *Antioxid. Redox. Signal* 2007;9:2277–2293. [PubMed: 17979528]
- Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. *Physiol Rev* 2006;86:1133–1149. [PubMed: 17015486]
- Zhou H, Gurley EC, Jarujaron S, Ding H, Fang Y, Xu Z, Pandak WM Jr, Hylemon PB. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. *AJP - Gastrointestinal and Liver Physiology* 2006;291:G1071–G1080.
- Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. *Mol. Pharmacol* 2005;68:690–700. [PubMed: 15976036]
- Wu X, Sun L, Zha W, Studer E, Gurley E, Chen L, Wang X, Hylemon PB, Pandak WM Jr, Sanyal AJ, Zhang L, Wang G, Chen J, Wang JY, Zhou H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. *Gastroenterology* 2010;138:197–209. [PubMed: 19732776]
- Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomed Pharmacother* 2004;58:173–182. [PubMed: 15082340]

17. Granda BW, Giancarlo GM, von Moltke LL, Greenblatt DJ. Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. *J Pharmacol Toxicol Methods* 1998;40:235–239. [PubMed: 10465159]
18. Jiang B, Hebert VY, Khandelwal AR, Stokes KY, Dugas TR. HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. *Toxicol Lett* 2009;187:164–171. [PubMed: 19429260]
19. Chandra S, Mondal D, Agrawal KC. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. *Exp Biol Med (Maywood)* 2009;234:442–453. [PubMed: 19234050]
20. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. *Toxicol Appl Pharmacol* 2007;224:60–71. [PubMed: 17669453]
21. Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, Bastard JP, Maachi M, Azoulay S, Briggs M, Caron M, Capeau J. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. *Antivir Ther* 2007;12:489–500. [PubMed: 17668557]
22. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. *Cardiovasc Toxicol* 2004;4:287–302. [PubMed: 15470276]
23. Holtz WA, Turetzky JM, Jong YJ, O'Malley KL. Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. *J Neurochem* 2006;99:54–69. [PubMed: 16987235]
24. Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW, Kaufman RJ. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. *Proc Natl Acad Sci U S A* 2008;105:18525–18530. [PubMed: 19011102]
25. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. *Free Radic Biol Med* 2004;37:1499–1507. [PubMed: 15454290]
26. Patel D, Sawant KK. Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). *Drug Dev Ind Pharm* 2007;33:1318–1326. [PubMed: 18097805]
27. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. *Prog Lipid Res* 2003;42:81–92. [PubMed: 12547652]
28. Bode H, Schmidt W, Schulzke JD, Fromm M, Riecken EO, Ullrich R. Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6. *Ann N.Y.Acad.Sci* 2000;915:117–122. [PubMed: 11193566]
29. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. *PLoS One* 2008;3:e2516. [PubMed: 18575590]
30. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006;12:1365–1371. [PubMed: 17115046]
31. Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyo EM, Norrgren H, Holmgren B, Jansson M. Microbial Translocation Correlates with the Severity of Both HIV-1 and HIV-2 Infections. *J Infect Dis*.
32. Patel D, Sawant KK. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. *Curr Drug Deliv* 2009;6:419–424. [PubMed: 19534704]
33. Lu JL, Wang JC, Zhao SX, Liu XY, Zhao H, Zhang X, Zhou SF, Zhang Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. *Eur J Pharm Biopharm* 2008;69:899–907. [PubMed: 18434109]

34. Chen Y, Li G, Wu X, Chen Z, Hang J, Qin B, Chen S, Wang R. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. *Biol Pharm Bull* 2008;31:118–125. [PubMed: 18175953]
35. Colin WP. Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews* 1997;25:47–58.
36. Gershanik T, Benzeno S, Benita S. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. *Pharm Res* 1998;15:863–869. [PubMed: 9647351]
37. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermuller N, Otto HF, Autschbach F. Inflammatory bowel disease is associated with changes of enterocytic junctions. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G216–G228. [PubMed: 11408275]
38. Greaves DR, Channon KM. Inflammation and immune responses in atherosclerosis. *Trends Immunol* 2002;23:535–541. [PubMed: 12401406]
39. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *The New England Journal of Medicine* 2005;352:1685–1695. [PubMed: 15843671]
40. Li Y, Tabas I. The inflammatory cytokine response of cholesterol-enriched macrophages is dampened by stimulated pinocytosis. *J Leukoc.Biol* 2007;81:483–491. [PubMed: 17062603]
41. Long H, Shi T, Borm PJ, Maatta J, Husgafvel-Pursiainen K, Savolainen K, Krombach F. ROS-mediated TNF-alpha and MIP-2 gene expression in alveolar macrophages exposed to pine dust. *Part Fibre Toxicol* 2004;1:3. [PubMed: 15813983]

Figure 1. Effect of antioxidants on ritonavir-induced ROS production in IEC-6 cells

Cells were treated with vehicle control (DMSO), positive control (H₂O₂, 10 μ M), thapsigargin (TG, a known ER stress inducer, 100 nM), ritonavir (RTV, 15 μ M), RTV with vitamin C (VC 15 μ g/ml) or, vitamin E (VE 20 μ g/ml), or ethyl linoleate (EL, 20 μ g/ml) or oleic acid (OA, 10 μ g/ml) for 4h. The intracellular ROS levels were measured as described in "Methods".

Values are mean $\pm$ SD of 3 independent experiments and analyzed using one-way ANOVA, Statistical significance relative to control, * p < 0.05 or relative to RTV, # p < 0.05.

Figure 2. Effect of antioxidants on ritonavir-induced ER stress and UPR activation in IEC-6 cells
A. IEC-6 cells stably transfected with pSEAP plasmid were treated with vehicle control (DMSO), ritonavir (RTV, 15 μ M) in the absence or presence of individual antioxidant, vitamin C (VC 15 μ g/ml) or, vitamin E (VE 20 μ g/ml), or ethyl linoleate (EL, 20 μ g/ml) or oleic acid (OA, 10 μ g/ml) or TG (100 nM) for 24 h. Activity of SEAP was measured as described under “Methods” and expressed as percent of control. Values are mean $\pm$ SD of 3 independent experiments. Statistical significance relative to vehicle control, * p <0.05 or relative to RTV, # p <0.05. **B.** Representative immunoblots against CHOP and lamin B from the nuclear extracts of IEC-6 cells treated with ritonavir (RTV, 15 μ M) in the absence or presence of individual antioxidant, vitamin C (VC 15 μ g/ml) or, vitamin E (VE 20 μ g/ml), or ethyl linoleate (EL, 20

μg/ml or 40 μg/ml) or oleic acid (OA, 10 μg/ml) for 4 h. Lamin B was used as a loading control of nuclear protein. Relative protein levels of CHOP from three independent experiments. Statistical significance relative to control, * $p < 0.05$ or relative to RTV, # $p < 0.05$.

Figure 3. Characterization of ritonavir SMEDDS

A: Particle size distribution of SMEDDS in water. 1: blank SMEDDS 46.1 nm; 2: RTV SMEDDS 81.6 nm. B–C: Zeta potential of SMEDDS, B: blank SMEDDS 1.94 mv; C: RTV SMEDDS 1.70 mv.

Figure 4. Stability and pharmacokinetics of ritonavir SMEDDS

A. The stability of ritonavir SMEDDS (RTV ME), and Norvir® in medium. RTV ME and Norvir® (25 μ M) were incubated in cell culture medium at 37°C for 4, 24 and 48 h. The remaining ritonavir in medium was determined by HPLC as described in “Methods”. B. IEC-6 cells were treated with 15 μ M ritonavir SMEDDS (RTV ME), Norvir® or ritonavir in DMSO (RTV DMSO) for 0.25, 0.5, 1, 2, 4, 8 and 24 h. The intracellular ritonavir concentration was determined by HPLC as described in “Methods” and normalized to total protein amount. Each data represents mean $\pm$ S.E. of three experiments. C. The *in vivo* Pharmacokinetics of RTV ME. Sprague-Dawley rats were gavaged with RTV ME or Norvir® at a dose of 50 mg/kg. The plasma concentration of ritonavir was determined as described in “Methods”.

Figure 5. Cell viability assay in IEC-6 cells

IEC-6 cells were seeded on 96-well plates for overnight, then treated with 25 μ M of ritonavir SMEDDS (RTV ME), Norvir®, or ritonavir in DMSO (RTV DMSO) for 24 h. The cell viability was determined using Cell Proliferation Reagent WST-1 as described in “Methods”. Each data represents mean $\pm$ SD. of three experiments. Statistical significance relative to control, * p < 0.05 or relative to RTV, # p < 0.05.

Figure 6. Effect of ritonavir SMEDDS and Norvir® on ROS production in IEC-6 cells

Cells were treated with vehicle control (DMSO), positive control (H₂O₂, 10 μ M), ritonavir in DMSO (RTV DMSO, 15 μ M), blank SMEDDS (blank ME), ritonavir SMEDDS (RTV ME, 15 μ M), and Norvir® (15 μ M) for 4h. The intracellular ROS levels were determined using H₂DCFDA as described in "Methods". Each bar represents mean $\pm$ SD of three experiments. Statistical significance relative to DMSO control, * p < 0.05 and relative to RTV DMSO, # p < 0.05.

Figure 7. Effect of ritonavir SMEDDS on ER stress and UPR activation in IEC-6 cells
A. IEC-6 cells stably transfected with pSEAP plasmid were treated with vehicle control (DMSO), ritonavir in DMSO (RTV DMSO, 15 μ M), ritonavir SMEDDS (RTV ME, 15 μ M) or Norvir® (15 μ M), or TG (25 nM) for 24 h. Activity of SEAP was measured as described under “Methods” and expressed as percent of control. Values are mean $\pm$ SD of 3 independent experiments. Statistical significance relative to vehicle control, * p < 0.05, or relative to RTV DMSO, # p < 0.05. **B.** Representative immunoblots against CHOP and lamin B from the nuclear extracts of IEC-6 cells treated with vehicle control (DMSO), ritonavir in DMSO (RTV DMSO, 15 μ M), ritonavir SMEDDS (RTV ME, 15 μ M) or Norvir® (15 μ M), or TG (25 nM) for 4 h. Lamin B was used as a loading control of nuclear protein. Relative protein levels of CHOP

from three independent experiments were analyzed. Statistical significance relative to control, $*p < 0.05$ or relative to RTV DMSO, $\#p < 0.05$.

Figure 8. Effect of ritonavir SMEDDS on intestinal permeability and tissue damages *in vivo*
 Wild type C57BL/6 mice were treated with control solution (PBS), blank SMEDDS(Blank ME), ritonavir SMEDDS (RTV ME) or Norvir® (50 mg/kg) for 4 weeks. A. The intestinal permeability was measured using FITC-dextran as described in “Methods”. Statistical significance relative to vehicle control (n=5), * $p<0.05$, ** $p<0.01$. B. Representative images of HE staining for each treatment group are shown.

Table 1

Solubility studies in various vehicles

Name of vehicles	Solubility in mg/ml $\pm$ SD
ethyl linoleate	5.5 $\pm$ 0.2
ethanol with 1% VC	> 150mg
cremophol EL	97.3 $\pm$ 2.2
oleic acid	> 150mg
ethyl linoleate/oleic acid(3/1)	141.7 $\pm$ 2.5
ethyl linoleate/cremophol EL(1/1)	79.3 $\pm$ 1.8